Kinins—II pp 67-82 | Cite as

Determination of Prekallikrein in Plasma by Means of a Chromogenic Tripeptide Substrate for Plasma Kallikrein

  • P. Friberger
  • E. Eriksson
  • S. Gustavsson
  • G. Claeson
Part of the Advances in Experimental Medicine and Biology book series (AEMB)


A method for plasma prekallikrein determination utilizing a chromo-genic tripeptide substrate is presented. The method has a good reproducibility and can easily be automized. Several parameters have been optimized. By using mixtures of deficient plasmas and pooled normal plasma or purified factors it was proved that prekallikrein was the factor determined and that more than 10% (of normal plasma concentration) of FXII and HMW kininogen were essential for the activation of prekallikrein in our method. Further experiments showed that the method was fairly selective and was not influenced by inhibitors present in normal plasma. The later finding was attributed to the high dilution of plasma made possible by using a potent activator and a sensitive substrate.


Dextran Sulphate Sodium Ellagic Acid Normal Plasma Dextran Sulphate Flufenamic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Amundsen, E. and Svendsen, L.: A new method for plasma kallikrein utilizing a synthetic chromogenic substrate. In: New methods for the analysis of coagulation using chromogenic substrates. Ed. I. Witt, Walter de Gruyter. p. 211, 1977.Google Scholar
  2. 2.
    Aurell, L., Friberger, P., Karlsson, G. and Claeson, G.: A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb. Res. II: 595–609, 1977.Google Scholar
  3. 3.
    Bang, N.U. and Mattler, L.E.: Serine Protease Specificity for Peptide Chromogenic Substrates. Thromb. Haemost. 38: 776–92, 1977.PubMedGoogle Scholar
  4. 4.
    Burrowes, C.E., Habal, F.M. and Movat, H.Z.: The inhibition of human plasma kallikrein by antithrombia III. Thromb. Res. 7: 175–83, 1975.PubMedCrossRefGoogle Scholar
  5. 5.
    Claeson, G., Friberger, P., Knds, M., and Eriksson, E.: Methods for determination of prekallikrein in plasma, glandular kallikrein and urokinase. Haemostasis 7: 76–78, 1978.PubMedGoogle Scholar
  6. 6.
    Donaldson, V.H., Glueck, H.I., Míller, M.A., Movat, H.Z. and Habal, F.: Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J. Lab. Clin. Med. 87: 327–37, 1976.PubMedGoogle Scholar
  7. 7.
    Egberg, N. and Bergstrom, K.: Studies on assays for plasma prekallikrein and for the monitoring of cumarol therapy. Haemostasis 7: 85–91, 1978.PubMedGoogle Scholar
  8. 8.
    Friberger, P., Knos, M., Gustafsson, S., Aurell, L. and Claeson, G.: A new specific substrate for the determination of plasmin activity. In: Chromogenic Substrates. Ed. V.V. Kakkar. Churchill Livingstone. In press.Google Scholar
  9. 9.
    Gallimore, T.M., Fareid, E. and Stormorken, H.: The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb. Res. 12: 409–20, 1978.PubMedCrossRefGoogle Scholar
  10. 10.
    Griffin, J.H.: Role of surface-dependent activation of Hageman factor (Blood coagulation Factor XII). Proc. Natl. Acad. Sci. 75: 1998–2002, 1978.PubMedCrossRefGoogle Scholar
  11. 1l.
    Kaplan, A.P., Meier, H.L. and Mandle, R.: The Hageman factor dependent pathway of coagulation, fibrinolysis and kinin generation. Seminars in Thrombosis and Haemostasis 3: 1–26, 1976.Google Scholar
  12. 12.
    Kluft, C.: Blood Fibrinolysis. Preactivators and activators in human plasma. Thesis. Dutch Efficiency Bureau-Pijnacker. p. 104, 1978.Google Scholar
  13. 13.
    Meier, H.L., Scott, C.F., Mandle, R., Webster, M.E., Pierce, J.V., Colman, R.W., and Kaplan, A.P.: Requirements for contact activation of human Hageman factor. Ann. N.Y. Acad. Sci. 283: 93–103, 1977.CrossRefGoogle Scholar
  14. 14.
    Schreiber, A.D.: Plasma inhibitors of the Hageman factor dependent pathways. Seminars in Thrombosis and Haemostasis 3: 43–51, 1976.Google Scholar
  15. 15.
    Wiggins, R.C., Bouma, B.N., Cochrane, C.G. and Griffin, J.H.: Role of high-molecular-weight kininogen in surface binding and activation of coagulation Factor XI and prekallikrein. Proc. Natl. Acad. Sci. 74: 4634–40, 1977.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1979

Authors and Affiliations

  • P. Friberger
    • 1
  • E. Eriksson
    • 1
  • S. Gustavsson
    • 1
  • G. Claeson
    • 1
  1. 1.Peptide ResearchAB KabiMölndalSweden

Personalised recommendations